Beryllium-Induced Hypersensitivity: Genetic Susceptibility and Neoantigen Generation

Andrew P. Fontenot, Michael T. Falta, John W. Kappler, Shaodong Dai and Amy S. McKee
J Immunol January 1, 2016, 196 (1) 22-27; DOI: https://doi.org/10.4049/jimmunol.1502011

Abstract

Chronic beryllium (Be) disease is a granulomatous lung disorder that results from Be exposure in a genetically susceptible host. The disease is characterized by the accumulation of Be-responsive CD4+ T cells in the lung, and genetic susceptibility is primarily linked to HLA-DPB1 alleles possessing a glutamic acid at position 69 of the β-chain. Recent structural analysis of a Be-specific TCR interacting with a Be-loaded HLA-DP2–peptide complex revealed that Be is coordinated by amino acid residues derived from the HLA-DP2 β-chain and peptide and showed that the TCR does not directly interact with the Be2+ cation. Rather, the TCR recognizes a modified HLA-DP2–peptide complex with charge and conformational changes. Collectively, these findings provide a structural basis for the development of this occupational lung disease through the ability of Be to induce posttranslational modifications in preexisting HLA-DP2–peptide complexes, resulting in the creation of neoantigens.

Beryllium (Be) is a rare alkaline earth metal that is used in a variety of high-technology industries, including aerospace, ceramics, electronics, and nuclear defense (1). Be exposure primarily occurs through inhalation of particulates by workers involved in the machining of Be-containing products. More than 1 million individuals have been exposed to Be in the workplace; in 2004, it was estimated that ∼140,000 United States workers were exposed to Be (2). The United States is the leading producer and consumer of Be products, using 250 tons in 2013 (3). The adverse health effects of Be exposure became apparent in the 1930s (4–7). With the introduction of Be-exposure standards in 1949, the occurrence of acute berylliosis was virtually eliminated, but cases of chronic Be disease (CBD) continue to occur. Depending on the nature of the exposure and the genetic susceptibility of the individual, CBD will develop in 1–16% of exposed subjects (reviewed in Ref. 1). Thus, CBD remains an important public health concern.

Workplace screening of Be-exposed workers identified individuals sensitized to Be but having no evidence of lung disease. These Be-sensitized (BeS) subjects have a Be-specific immune response in peripheral blood but no clinical or pathologic features of CBD (8). The rate of progression from Be sensitization to disease is difficult to assess; a subset of BeS subjects progressed to CBD at a rate of 6–8% per year (8, 9). Although Be sensitization is required for the development of CBD, not all BeS subjects progress to CBD, suggesting that differences in exposure and/or genetic factors may contribute to disease progression. CBD is characterized by noncaseating granulomatous inflammation and alveolitis composed of Be-specific CD4+ T cells. Granulomas primarily occur in the lung, although other organ systems may be involved (10). Diagnosis of CBD requires the detection of a Be-specific immune response in blood and/or lung (11) and the presence of noncaseating granulomatous inflammation on a biopsy specimen (12). The pathology of CBD is identical to that seen in sarcoidosis, a more common granulomatous lung disease of unknown etiology (13). Because of the persistence of Be in the lung years after exposure cessation (14), the natural history of disease is characterized by a gradual decline in lung function, with one third of untreated patients historically progressing to end-stage respiratory insufficiency (15).

Over the past decade, major advances in our understanding of the pathogenesis of Be-induced disease have occurred. This review focuses on recent advances in our understanding of T cell recognition of Be and the interaction between environmental exposure and genetic susceptibility in the genesis of granulomatous inflammation.

Be-induced innate immune activation

In addition to its ability to serve as an antigenic stimulus, Be functions as an adjuvant in immune responses (Fig. 1A). For example, rabbits vaccinated with trichostrongylus extracts combined with Be demonstrated increased protection against parasitic challenge compared with mice vaccinated with extract alone (16). Lee et al. (17) showed that the adjuvant properties of Be were due to its ability to increase IFN-γ secretion. Adjuvants typically operate via engagement of pattern recognition receptors that drive activation and maturation of APCs. Exposure of macrophages and dendritic cells (DCs) to Be induced the release of inflammatory chemokines, cytokines, and reactive oxidative species (18–22). Li et al. (23) showed that exposure of monocyte-derived DCs induced phosphorylation of MAPK p38, resulting in NF-κB activation and enhanced production of IFN-γ and TNF-α by Be-specific CD4+ T cells. In mice, pulmonary Be exposure rapidly induced cellular death and release of the alarmins DNA and IL-1α into the lung, followed by IL-1R–dependent expression of KC and neutrophil infiltration (24).

FIGURE 1.
FIGURE 1.

Pathogenesis of CBD. (A) Be exposure results in cellular death and the release of DNA and IL-1α into the lung, followed by IL-1R–dependent expression of KC and neutrophil recruitment. Ingestion of Be also results in DC activation and trafficking to lung-draining lymph nodes. (B) DCs expressing HLA-DP molecules with a glutamic acid at amino acid position 69 of the β-chain present Be (red stars) to CD4+ T cells, resulting in T cell activation, proliferation, and trafficking to the lung. (C) Clonally expanded CD4+ T cells in the lung are CD28 independent, express an effector memory T cell phenotype, and secrete Th1-type cytokines, including IFN-γ, IL-2, and TNF-α. The release of IFN-γ and TNF-α promotes macrophage accumulation, activation, and aggregation, resulting in the development of granulomatous inflammation. Within granulomas, HLA-DP–expressing APCs present the Be-peptide complex to Ag-experienced CD4+ T cells.

These innate pathways may drive acute berylliosis and contribute to Be sensitization in response to low-dose exposures in genetically susceptible individuals. Under steady-state conditions, DCs maintain tolerance to innocuous substances (25). In contrast, Be exposure enhanced migration of DCs to draining lymph nodes, upregulated the costimulatory molecules CD80 and CD86 on migratory DCs, and enhanced primary and memory CD4+ T cell responses to a model Ag (24). These adjuvant effects of Be required MyD88-dependent signaling pathways, unlike the vaccine adjuvant aluminum hydroxide, which enhances Ab production to bystander Ag via MyD88-independent pathways (24, 26). Thus, Be has a critical impact on DC function through innate receptor pathways that may have important contributions to disease pathogenesis.

Be-specific CD4+ T cells in CBD

The lungs of CBD patients are characterized by an influx of activated CD4+ T cells that play a critical role in the pathogenesis of CBD (11, 27–30). After T cell recognition of Be, Ag-specific CD4+ T cells undergo clonal proliferation, differentiate into memory T cell subsets, and home to the lung (Fig. 1B, 1C). Be-specific CD4+ T cells in bronchoalveolar lavage fluid (BALF) express markers of previous activation (28, 31), recognize Be in a CD28 costimulation–independent manner (32), and exhibit an effector memory T cell phenotype (31, 33). In addition, Be-specific CD4+ T cells in BALF upregulate PD-1 (34) and CTLA-4 (35), coinhibitory receptors that negatively regulate T cell function (36). Upregulation of PD-1 on Be-specific CD4+ T cells dampens proliferation of these cells, thus playing a key role in preserving lung function in the presence of persistent Ag exposure.

Striking numbers of Be-responsive, Th1-polarized CD4+ T cells are present in the BALF of CBD patients (31, 37), whereas Th2- or Th17-polarized T cells have not been detected (31, 37). The frequency of IFN-γ–producing CD4+ T cells in the BALF of CBD patients after BeSO4 stimulation ranged from 1.7 to 29% (31), whereas the frequency in blood ranged from undetectable to ∼1.0% (38, 39). Conversely, Be-responsive CD8+ T cells have not been detected in blood or BALF, suggesting that this T cell lineage plays a minor role, if any, in CBD. Although the vast majority of Be-specific cells are compartmentalized to the lung, greater numbers of circulating Be-specific cells strongly correlated with alveolar inflammation, as measured by BALF WBCs and lymphocyte counts (38, 39). Thus, the number of circulating Be-specific CD4+ T cells may provide a glimpse into the lung without the need for invasive procedures.

Public CD4+ T cells in BALF of CBD patients

CD4+ T cells recognize Ag presented by MHC class II (MHCII) molecules via a surface receptor composed of α- and β-chains (40). TCR α-chain (TCRA) and TCR β-chain (TCRB) genes are formed through somatic rearrangement of germline gene segments, and the expressed TCRB genes are generated from rearrangement of variable (V) to diversity (D) to junctional (J) region gene segments. The highly variable junctional region forms the CDR3, which is critically involved in the TCR’s interaction with the MHC-peptide complex. With the αβTCR repertoire being estimated at >107 possibilities (41), there is little chance that any two expanded T cell clones will express nearly identical TCRs unless selected by the same MHC-peptide complex.

Studies of TCR expression on CD4+ T cells from ex vivo BALF of CBD patients demonstrated the presence of oligoclonal T cell populations that were specific for CBD and not seen in other diseases, such as sarcoidosis (29, 30). Certain TCR β-chain variable (Vβ) region motifs were enriched in lung CD4+ T cells from CBD patients and persisted at high frequency in subjects with persistent disease (29, 30). In addition, we identified a public Vβ5.1+ TCR repertoire in BALF CD4+ T cells in all HLA-DP2–expressing CBD patients who were evaluated (42). These Ag-specific public Vβ5.1 chains were paired with different α-chains, and their frequency was inversely correlated with a loss of lung function and exercise capacity, suggesting a pathogenic role for this T cell subset in CBD (42). Public T cells are defined by the expression of identical TCR Vα and/or Vβ genes that are present in the majority of subjects in response to a specific epitope. Despite public repertoires being restricted in nature, they are typically dominant and dictate disease severity (43–47). Most public repertoires were identified in MHC class I–restricted CD8+ T cells (48–50). Conversely, public repertoires have rarely been detected in the CD4+ T cell subset as a result, in most cases, of unknown stimulatory Ags. For CBD, the use of Be-loaded HLA-DP2–peptide tetramers (described below) facilitated the identification of epitope-specific public CD4+ T cells and suggests that public CD4+ T cells are more common than previously thought.

Genetic susceptibility to CBD

In addition to workplace exposure to Be, genetic susceptibility plays an essential role in the development of Be-induced disease. Saltini et al. (27) demonstrated that BALF CD4+ T cells from CBD patients recognized Be in an MHCII–restricted manner and subsequently showed that genetic susceptibility was most strongly associated with a particular MHCII molecule, HLA-DP (51). This study demonstrated that HLA-DPB1 alleles with a glutamic acid (E) at position 69 of the β-chain (βGlu69) were strongly linked to disease susceptibility (51), with the most prevalent βGlu69-containing allele being HLA-DPB1*02:01. Since the initial report, multiple studies corroborated these findings, documenting the presence of βGlu69-containing DPB1 alleles in 73–95% of BeS subjects and CBD patients compared with 30–48% of exposed controls (reviewed in Ref. 1). In CBD patients who do not express a βGlu69-containing HLA-DP allele, an increased frequency of HLA-DRB1*13:01 alleles was identified (52, 53). Importantly, these alleles possess an analogous glutamic acid residue at position 71 of the β-chain (βGlu71). In addition, several HLA-DR alleles that share a phenylalanine at position 47 of the β-chain were associated with disease in individuals lacking a βGlu69-containing HLA-DP allele (54). A differential risk for disease development was associated with certain rare βGlu69-containing DPB1 alleles, such as HLA-DPB1*17:01 (52, 55–57). Thus, Be-induced disease is a classic example of a disorder resulting from gene-by-environment interactions, where both components are required for disease development. In this regard, the probability of CBD increases with HLA-DP βGlu69 copy number and increasing workplace exposure to Be (58), suggesting that genetic and exposure factors may have an additive effect on the risk for disease development (59).

CD4+ T cell recognition of Be

Several groups showed that Be presentation occurs primarily through HLA-DP, with HLA-DR playing a minor role, particularly in subjects lacking a βGlu69-containing HLA-DP molecule (54, 60, 61). In individuals expressing HLA-DP βGlu69, Be-specific T cells were restricted only by HLA-DP alleles that contain βGlu69, and amino acid substitution at this position abolished T cell responses. Thus, the molecular mechanism for the genetic association of particular MHCII genes with disease was based on the ability of those proteins to bind and present Ag to pathogenic CD4+ T cells (60, 61).

Longstanding questions in CBD and other metal-induced hypersensitivities include the nature of metal interactions with MHCII molecules and the role of peptide in creating a ligand recognized by metal-specific TCRs. Saltini and colleagues (62) proposed that the properties of the p4 pocket of the HLA-DP–peptide–binding region, together with electron-donating amino acids derived from HLA-DP–binding peptides, could coordinate the positively charged Be ion. In addition to Be, specific peptides are required to complete the Be-specific αβTCR ligand (63, 64). However, a set of known HLA-DP2–binding peptides (65) did not induce IL-2 secretion by T cell hybridomas expressing Be-specific TCRs (64). We (64) identified Be-dependent mimotopes that bind to HLA-DP2 and form a complex with Be recognized by pathogenic CD4+ T cells in CBD. These Be-dependent mimotopes expressed negatively charged aspartic and glutamic acid residues at p4 (pD4) and p7 (pE7) of the peptide (64), and the location of these amino acids, in addition to βGlu69 contributed by the HLA-DP2 β-chain, suggested their role in Be coordination for T cell recognition.

Using human protein databases to identify endogenously derived peptides with homology to the mimotope sequences, plexin A peptides that bound HLA-DP2/Be and stimulated pathogenic CD4+ T cells from CBD patients were identified (64). Plexins are transmembrane proteins encoded by nine genes (PLXNA1–4, B1–3, C1, and D1) that are involved in cell movement and response (66). Only the plexin A family contains the stimulatory epitope that includes acidic amino acids at both the p4 and p7 positions (66). Using Be-loaded HLA-DP2–plexin A4 tetramers, we (64) identified tetramer-binding CD4+ T cells in the BALF of all HLA-DP2–expressing CBD patients who exhibited a Be-specific immune response in lung. Interestingly, the CD4+ T cells expressing the public Vβ5.1+ TCR were also specific for the HLA-DP2–plexin A/Be complex (42), strongly implicating plexin A as a relevant endogenous Ag in CBD.

Structural basis of CBD

To characterize the structural features of βGlu69-containing HLA-DP molecules that explain disease association, multiple HLA-DP2 (DPA1*01:03, DPB1*02:01) molecules were crystallized with self-peptides derived from HLA-DR α-chain, Ras, or HLA-A28 (63, 67). The overall structure of these HLA-DP2–peptide complexes was similar to that of other MHCII-peptide complexes; however, several unique features of this molecule likely contribute to the development of CBD. First, there was a widening of the peptide-binding groove between the peptide and the β-chain α-helix (63, 67), suggesting that the α-helix is flexible in this region and can roll away from the peptide and the floor of the binding groove. The net effect of this widening was a solvent-exposed acidic pocket composed of three glutamic acid residues on the HLA-DP2 β-chain: βGlu68 and βGlu69 from the β-chain α-helix and βGlu26 from the floor of the peptide-binding groove (63, 67). In addition to βGlu69, the HLA-DP2 crystal structure suggested that βGlu26 and βGlu68 may be involved in Be coordination and presentation. Site-directed mutagenesis of each of these glutamic acids to alanines abrogated the ability of Be-pulsed HLA-DP2–expressing fibroblasts to stimulate Be-specific TCRs (63). Because βGlu26 and βGlu68 are invariant among HLA-DP alleles (68), they were not identified in genetic analyses of linkage between HLA-DPB1 alleles and CBD, and their presence is not sufficient for Be presentation in the absence of βGlu69. Because βGlu69 is the most important polymorphism associated with the genetic susceptibility to Be-induced disease and solved structures of other Be-associated proteins show Be coordination by acidic amino acids (69), these findings suggested that this acidic pocket is the Be binding site within the TCR footprint of HLA-DP2.

Recently, we (67) crystallized an HLA-DP2 mimotope/Be-specific AV22 TCR complex to a resolution of 2.8 Å (PDB ID code 4P4R). In this structure, the acidic pocket included two additional acidic amino acids contributed by the peptide at positions p4 and p7 (67). Surface plasmon resonance TCR binding experiments and mutational studies confirmed that the acidic properties of pD4, pE7, and βGlu69 were essential for Be presentation (67). Upon Be binding to HLA-DP2, the acidic pocket underwent a conformational rearrangement that captured the Be2+ and an accompanying cation through interactions via the carboxylates of βGlu69 and other HLA-DP2 and mimotope oxygens (67). Surprisingly, neither Be2+ nor Na+ was accessible on the surface of the complex for direct TCR interaction (Fig. 2A). However, the presence of these cations reduced the electrostatic surface potential and subtly altered the surface topology of the HLA-DP2 mimotope complex over the cation binding site where the AV22 TCR Vβ CDR3 interacts (Fig. 2), indicating that both of these changes likely contributed to creation of the αβTCR ligand (67). It is widely believed that nonpeptide moieties, such as metals, trinitrophenol, or fluorescein, are recognized by T cells as haptens (i.e., bind to the surface of the MHC-peptide complex and participate in TCR engagement) (70, 71). However, our structural data show that Be is not functioning as a hapten but rather indirectly induces changes in surface charge and topology that convert a tolerized self-peptide into a neoantigen. In essence, Be becomes part of the internal structure of the complex and represents a novel posttranslational modification.

FIGURE 2.
FIGURE 2.

Be-induced alterations in the structure of the HLA-DP2 mimotope 2 (M2) complex. (A) Comparison of the electrostatic surface potential map of the HLA-DP2–M2 complex in the absence (left panel) and presence (right panel) of Be (PDB ID code 4P4R) (67). In both cases, the water-accessible surfaces surrounding the Be2+/Na+ binding site of the HLA-DP2–M2 complex are shown, looking directly at the areas of contact. The surface is colored by the electrostatic surface potential (red, negative; blue, positive). Gluβ68 underwent the most significant change and is circled on the surface map. (B) Conformational changes of the residues involved in Be2+/Na+ coordination. Side chains of Gluβ26, Gluβ68, and Gluβ69 of the HLA-DP2 β1 helix (magenta) and p4D and p7E of the M2 peptide (yellow) are shown in sticks with CPK coloring. Be2+ and Na+ are shown as green and gold spheres, respectively.

Requirement of HLA-DP2 expression for the development of a murine model of CBD

Exposure of multiple inbred strains of mice to Be failed to lead to the development of a viable murine model of CBD (72). With the generation of HLA-DP2–transgenic mice (73), we exposed these mice to BeO and noted the development of peribronchovascular mononuclear infiltrates and an HLA-DP2–restricted, Th1-polarized Be-specific immune response (74). Using Be-loaded HLA-DP2–plexin A4 tetramers, CD4+ T cells derived from the lungs of BeO-exposed HLA-DP2–transgenic mice recognized identical αβTCR ligands as T cells from HLA-DP2–expressing CBD patients (74). This study confirmed the importance of HLA-DP2 and likely other βGlu69-containing HLA-DP molecules in the generation of CBD.

Nickel- and drug-induced hypersensitivity

Metal ions, such as Ni, Co, and Cu, can induce allergic hypersensitivity. Ni is the most common contact allergen, with 10% of the white population having positive skin reactions (75). Unlike Be-specific T cells, some Ni-reactive T cell clones cross-react with other transitional metals, such as Cu and Pb (76), with no particular MHCII allelic association noted in some nickel-allergic subjects (77). However, MHCII-restricted CD4+ T cells have been identified (78), and studies suggest that Ni can bind to histidine residues derived from either the peptide (79) or the MHCII molecule (80). In this regard, we (80) showed that T cell recognition of Ni required HLA-DR52c with a specific unknown peptide(s) and was dependent on a histidine residue at position 81 of the MHCII β-chain. Thus, unlike Be, Ni acts as a hapten and directly participates in TCR engagement.

Severe allergic reactions to abacavir, a reverse-transcriptase inhibitor used in the treatment of HIV infection, were described recently and are strongly linked to HLA-B alleles (81). Structural and biochemical studies showed that abacavir binds within the HLA-B peptide-binding groove and restricts the repertoire of bound self-peptides, resulting in the generation of an exuberant polyclonal CD8+ T cell response that resembles an allogeneic response (82, 83). This is reminiscent of T cell recognition of Be, in which the Be2+ cation also binds within the peptide-binding groove of HLA-DP2 without being part of the TCR interface. However, unlike abacavir, Be modifies the αβTCR ligand without changing the HLA-DP2 bound self-peptide or restricting the peptide repertoire, as evidenced by the ability of fixed Be-pulsed APCs to stimulate Be-specific CD4+ T cells (84). Collectively, the recent findings in Be-, Ni-, and abacavir-induced hypersensitivity show how the addition of diverse small molecules can alter the topology of the MHC-peptide complex, generating neoantigens and Ag-specific immune responses directed against these previously tolerized self-peptides.

Conclusions

Recent progress defining the adjuvant properties of Be, unique structural features of HLA-DP2, stimulatory peptides that capture and coordinate Be, and structural changes induced by Be to the MHCII-peptide complex provides an explanation for the gene-by-environment interactions that lead to CBD. Similarity exists in the manner in which small molecules, such as drugs, can associate with certain HLA molecules and induce idiosyncratic reactions. The ability of Be and other small molecules to generate neoantigens also suggests similarity to autoimmunity, in which posttranslational modifications can alter peptide binding to the MHCII molecule and potentially T cell recognition. Thus, recent findings suggest that allergy hypersensitivities and autoimmunity may not be distinct disease processes but exist on a continuum.

Disclosures

The authors have no financial conflicts of interest.

Footnotes

  • This work was supported by National Institutes of Health grants (HL62410, HL92997, and ES011810 [to A.P.F.], ES25797 [to S.D.], and the Clinical and Translational Sciences Institute [UL1 TR000154] from the National Center for Advancing Translational Sciences), as well as the Boettcher Foundation (to S.D.) and an Unrestricted Grant from the American Thoracic Society (to A.S.M.).

  • Abbreviations used in this article:

    BALF
    bronchoalveolar lavage fluid
    Be
    beryllium
    BeS
    Be sensitized
    CBD
    chronic Be disease
    DC
    dendritic cell
    MHCII
    MHC class II.

  • Received September 10, 2015.
  • Accepted October 20, 2015.

References

  1. ↵
    1. Balmes J. R.,
    2. J. L. Abraham,
    3. R. A. Dweik,
    4. E. Fireman,
    5. A. P. Fontenot,
    6. L. A. Maier,
    7. J. Muller-Quernheim,
    8. G. Ostiguy,
    9. L. D. Pepper,
    10. C. Saltini,
    11. et al,
    12. ATS Ad Hoc Committee on Beryllium Sensitivity and Chronic Beryllium Disease
    . 2014. An official American Thoracic Society statement: diagnosis and management of beryllium sensitivity and chronic beryllium disease. Am. J. Respir. Crit. Care Med. 190: e34–e59.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Henneberger P. K.,
    2. S. K. Goe,
    3. W. E. Miller,
    4. B. Doney,
    5. D. W. Groce
    . 2004. Industries in the United States with airborne beryllium exposure and estimates of the number of current workers potentially exposed. J. Occup. Environ. Hyg. 1: 648–659.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Jaskula B. W.
    2015. 2013 Minerals Yearbook. U.S. Geological Survey, Washington, D.C.
  4. ↵
    1. Weber H.,
    2. W. E. Engelhardt
    . 1933. Investigation of dust arising out of beryllium extraction. Gewerbehyg Unfallverhuet. 10: 41.
    OpenUrl
    1. Gelman I.
    1936. Poisoning by vapors of beryllium oxyfluoride. J. Ind. Hyg. Toxicol. 18: 371–399.
    OpenUrl
    1. Berkovits M.,
    2. B. Izreal
    . 1940. Changes in the lungs by beryllium oxyfluoride. Klin. Med. (Mosk.) 18: 117–122.
    OpenUrl
  7. ↵
    1. Hardy H. L.,
    2. I. R. Tabershaw
    . 1946. Delayed chemical pneumonitis occurring in workers exposed to beryllium compounds. J. Ind. Hyg. Toxicol. 28: 197–211.
    OpenUrlPubMed
  8. ↵
    1. Newman L. S.,
    2. M. M. Mroz,
    3. R. Balkissoon,
    4. L. A. Maier
    . 2005. Beryllium sensitization progresses to chronic beryllium disease: a longitudinal study of disease risk. Am. J. Respir. Crit. Care Med. 171: 54–60.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Seidler A.,
    2. U. Euler,
    3. J. Müller-Quernheim,
    4. K. I. Gaede,
    5. U. Latza,
    6. D. Groneberg,
    7. S. Letzel
    . 2012. Systematic review: Progression of beryllium sensitization to chronic beryllium disease. Occup. Med. (Lond.) 62: 506–513.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Fontenot A. P.,
    2. B. L. Kotzin
    . 2003. Chronic beryllium disease: immune-mediated destruction with implications for organ-specific autoimmunity. Tissue Antigens 62: 449–458.
    OpenUrlCrossRefPubMed
  11. ↵
    1. Rossman M. D.,
    2. J. A. Kern,
    3. J. A. Elias,
    4. M. R. Cullen,
    5. P. E. Epstein,
    6. O. P. Preuss,
    7. T. N. Markham,
    8. R. P. Daniele
    . 1988. Proliferative response of bronchoalveolar lymphocytes to beryllium. A test for chronic beryllium disease. Ann. Intern. Med. 108: 687–693.
    OpenUrlCrossRefPubMed
  12. ↵
    1. Newman L. S.,
    2. K. Kreiss,
    3. T. E. King Jr..,
    4. S. Seay,
    5. P. A. Campbell
    . 1989. Pathologic and immunologic alterations in early stages of beryllium disease. Re-examination of disease definition and natural history. Am. Rev. Respir. Dis. 139: 1479–1486.
    OpenUrlCrossRefPubMed
  13. ↵
    1. Newman L. S.,
    2. C. S. Rose,
    3. L. A. Maier
    . 1997. Sarcoidosis. N. Engl. J. Med. 336: 1224–1234.
    OpenUrlCrossRefPubMed
  14. ↵
    1. Williams W. J.,
    2. D. Kelland
    . 1986. New aid for diagnosing chronic beryllium disease (CBD): laser ion mass analysis (LIMA). J. Clin. Pathol. 39: 900–901.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Newman L. S.,
    2. J. Lloyd,
    3. E. Daniloff
    . 1996. The natural history of beryllium sensitization and chronic beryllium disease. Environ. Health Perspect. 104(Suppl. 5): 937–943.
    OpenUrlCrossRefPubMed
  16. ↵
    1. Wedrychowicz H.,
    2. I. Romanik,
    3. E. Szczygielska,
    4. B. Bezubik
    . 1992. The effect of adjuvant and specific or non-specific vaccination on development of protective immunity of rabbits against Trichostrongylus colubriformis infection. Int. J. Parasitol. 22: 991–996.
    OpenUrlCrossRefPubMed
  17. ↵
    1. Lee J. Y.,
    2. O. Atochina,
    3. B. King,
    4. L. Taylor,
    5. M. Elloso,
    6. P. Scott,
    7. M. D. Rossman
    . 2000. Beryllium, an adjuvant that promotes gamma interferon production. Infect. Immun. 68: 4032–4039.
    OpenUrlAbstract/FREE Full Text
  18. ↵
    1. Hong-Geller E.,
    2. P. E. Pardington,
    3. R. B. Cary,
    4. N. N. Sauer,
    5. G. Gupta
    . 2006. Chemokine regulation in response to beryllium exposure in human peripheral blood mononuclear and dendritic cells. Toxicology 218: 216–228.
    OpenUrlCrossRefPubMed
    1. Amicosante M.,
    2. F. Berretta,
    3. A. Franchi,
    4. P. Rogliani,
    5. C. Dotti,
    6. M. Losi,
    7. R. Dweik,
    8. C. Saltini
    . 2002. HLA-DP-unrestricted TNF-α release in beryllium-stimulated peripheral blood mononuclear cells. Eur. Respir. J. 20: 1174–1178.
    OpenUrlAbstract/FREE Full Text
    1. Sawyer R. T.,
    2. L. A. Kittle,
    3. H. Hamada,
    4. L. S. Newman,
    5. P. A. Campbell
    . 2000. Beryllium-stimulated production of tumor necrosis factor-α by a mouse hybrid macrophage cell line. Toxicology 143: 235–247.
    OpenUrlCrossRefPubMed
    1. Galbraith G. M.,
    2. J. P. Pandey,
    3. M. G. Schmidt,
    4. P. Arnaud,
    5. J. M. Goust
    . 1996. Tumor necrosis factor alpha gene expression in human monocytic THP-1 cells exposed to beryllium. Arch. Environ. Health 51: 29–33.
    OpenUrlCrossRefPubMed
  22. ↵
    1. Sawyer R. T.,
    2. D. R. Dobis,
    3. M. Goldstein,
    4. L. Velsor,
    5. L. A. Maier,
    6. A. P. Fontenot,
    7. L. Silveira,
    8. L. S. Newman,
    9. B. J. Day
    . 2005. Beryllium-stimulated reactive oxygen species and macrophage apoptosis. Free Radic. Biol. Med. 38: 928–937.
    OpenUrlCrossRefPubMed
  23. ↵
    1. Li L.,
    2. Z. Huang,
    3. M. Gillespie,
    4. P. M. Mroz,
    5. L. A. Maier
    . 2014. p38 Mitogen-Activated Protein Kinase in beryllium-induced dendritic cell activation. Hum. Immunol. 75: 1155–1162.
    OpenUrlCrossRefPubMed
  24. ↵
    1. McKee A. S.,
    2. D. G. Mack,
    3. F. Crawford,
    4. A. P. Fontenot
    . 2015. MyD88 dependence of beryllium-induced dendritic cell trafficking and CD4(+) T-cell priming. Mucosal Immunol. 8: 1237–1247.
    OpenUrlCrossRefPubMed
  25. ↵
    1. Tsitoura D. C.,
    2. R. H. DeKruyff,
    3. J. R. Lamb,
    4. D. T. Umetsu
    . 1999. Intranasal exposure to protein antigen induces immunological tolerance mediated by functionally disabled CD4+ T cells. J. Immunol. 163: 2592–2600.
    OpenUrlAbstract/FREE Full Text
  26. ↵
    1. Schnare M.,
    2. G. M. Barton,
    3. A. C. Holt,
    4. K. Takeda,
    5. S. Akira,
    6. R. Medzhitov
    . 2001. Toll-like receptors control activation of adaptive immune responses. Nat. Immunol. 2: 947–950.
    OpenUrlCrossRefPubMed
  27. ↵
    1. Saltini C.,
    2. K. Winestock,
    3. M. Kirby,
    4. P. Pinkston,
    5. R. G. Crystal
    . 1989. Maintenance of alveolitis in patients with chronic beryllium disease by beryllium-specific helper T cells. N. Engl. J. Med. 320: 1103–1109.
    OpenUrlCrossRefPubMed
  28. ↵
    1. Saltini C.,
    2. M. Kirby,
    3. B. C. Trapnell,
    4. N. Tamura,
    5. R. G. Crystal
    . 1990. Biased accumulation of T lymphocytes with “memory”-type CD45 leukocyte common antigen gene expression on the epithelial surface of the human lung. J. Exp. Med. 171: 1123–1140.
    OpenUrlAbstract/FREE Full Text
  29. ↵
    1. Fontenot A. P.,
    2. M. T. Falta,
    3. B. M. Freed,
    4. L. S. Newman,
    5. B. L. Kotzin
    . 1999. Identification of pathogenic T cells in patients with beryllium-induced lung disease. J. Immunol. 163: 1019–1026.
    OpenUrlAbstract/FREE Full Text
  30. ↵
    1. Fontenot A. P.,
    2. B. L. Kotzin,
    3. C. E. Comment,
    4. L. S. Newman
    . 1998. Expansions of T-cell subsets expressing particular T-cell receptor variable regions in chronic beryllium disease. Am. J. Respir. Cell Mol. Biol. 18: 581–589.
    OpenUrlCrossRefPubMed
  31. ↵
    1. Fontenot A. P.,
    2. S. J. Canavera,
    3. L. Gharavi,
    4. L. S. Newman,
    5. B. L. Kotzin
    . 2002. Target organ localization of memory CD4(+) T cells in patients with chronic beryllium disease. J. Clin. Invest. 110: 1473–1482.
    OpenUrlCrossRefPubMed
  32. ↵
    1. Fontenot A. P.,
    2. L. Gharavi,
    3. S. R. Bennett,
    4. S. J. Canavera,
    5. L. S. Newman,
    6. B. L. Kotzin
    . 2003. CD28 costimulation independence of target organ versus circulating memory antigen-specific CD4+ T cells. J. Clin. Invest. 112: 776–784.
    OpenUrlCrossRefPubMed
  33. ↵
    1. Fontenot A. P.,
    2. B. E. Palmer,
    3. A. K. Sullivan,
    4. F. G. Joslin,
    5. C. C. Wilson,
    6. L. A. Maier,
    7. L. S. Newman,
    8. B. L. Kotzin
    . 2005. Frequency of beryllium-specific, central memory CD4+ T cells in blood determines proliferative response. J. Clin. Invest. 115: 2886–2893.
    OpenUrlCrossRefPubMed
  34. ↵
    1. Palmer B. E.,
    2. D. G. Mack,
    3. A. K. Martin,
    4. M. Gillespie,
    5. M. M. Mroz,
    6. L. A. Maier,
    7. A. P. Fontenot
    . 2008. Up-regulation of programmed death-1 expression on beryllium-specific CD4+ T cells in chronic beryllium disease. J. Immunol. 180: 2704–2712.
    OpenUrlAbstract/FREE Full Text
  35. ↵
    1. Chain J. L.,
    2. A. K. Martin,
    3. D. G. Mack,
    4. L. A. Maier,
    5. B. E. Palmer,
    6. A. P. Fontenot
    . 2013. Impaired function of CTLA-4 in the lungs of patients with chronic beryllium disease contributes to persistent inflammation. J. Immunol. 191: 1648–1656.
    OpenUrlAbstract/FREE Full Text
  36. ↵
    1. Sharpe A. H.,
    2. G. J. Freeman
    . 2002. The B7-CD28 superfamily. Nat. Rev. Immunol. 2: 116–126.
    OpenUrlCrossRefPubMed
  37. ↵
    1. Tinkle S. S.,
    2. L. A. Kittle,
    3. B. A. Schumacher,
    4. L. S. Newman
    . 1997. Beryllium induces IL-2 and IFN-γ in berylliosis. J. Immunol. 158: 518–526.
    OpenUrlAbstract
  38. ↵
    1. Martin A. K.,
    2. D. G. Mack,
    3. M. T. Falta,
    4. M. M. Mroz,
    5. L. S. Newman,
    6. L. A. Maier,
    7. A. P. Fontenot
    . 2011. Beryllium-specific CD4+ T cells in blood as a biomarker of disease progression. J. Allergy Clin. Immunol. 128: 1100–1106.e1–5.
    OpenUrlCrossRef
  39. ↵
    1. Pott G. B.,
    2. B. E. Palmer,
    3. A. K. Sullivan,
    4. L. Silviera,
    5. L. A. Maier,
    6. L. S. Newman,
    7. B. L. Kotzin,
    8. A. P. Fontenot
    . 2005. Frequency of beryllium-specific, TH1-type cytokine-expressing CD4+ T cells in patients with beryllium-induced disease. J. Allergy Clin. Immunol. 115: 1036–1042.
    OpenUrlCrossRefPubMed
  40. ↵
    1. Marrack P.,
    2. J. Kappler
    . 1987. The T cell receptor. Science 238: 1073–1079.
    OpenUrlAbstract/FREE Full Text
  41. ↵
    1. Arstila T. P.,
    2. A. Casrouge,
    3. V. Baron,
    4. J. Even,
    5. J. Kanellopoulos,
    6. P. Kourilsky
    . 2000. Diversity of human αβ T cell receptors. Science 288: 1135.
    OpenUrlCrossRefPubMed
  42. ↵
    1. Bowerman N. A.,
    2. M. T. Falta,
    3. D. G. Mack,
    4. F. Wehrmann,
    5. F. Crawford,
    6. M. M. Mroz,
    7. L. A. Maier,
    8. J. W. Kappler,
    9. A. P. Fontenot
    . 2014. Identification of multiple public TCR repertoires in chronic beryllium disease. J. Immunol. 192: 4571–4580.
    OpenUrlAbstract/FREE Full Text
  43. ↵
    1. Wang G. C.,
    2. P. Dash,
    3. J. A. McCullers,
    4. P. C. Doherty,
    5. P. G. Thomas
    . 2012. T cell receptor αβ diversity inversely correlates with pathogen-specific antibody levels in human cytomegalovirus infection. Sci. Transl. Med. 4: 128ra42.
    OpenUrlAbstract/FREE Full Text
    1. Luo W.,
    2. J. Su,
    3. X. B. Zhang,
    4. Z. Yang,
    5. M. Q. Zhou,
    6. Z. M. Jiang,
    7. P. P. Hao,
    8. S. D. Liu,
    9. Q. Wen,
    10. Q. Jin,
    11. L. Ma
    . 2012. Limited T cell receptor repertoire diversity in tuberculosis patients correlates with clinical severity. PLoS One 7: e48117.
    OpenUrlCrossRefPubMed
    1. Frahm N.,
    2. P. Kiepiela,
    3. S. Adams,
    4. C. H. Linde,
    5. H. S. Hewitt,
    6. K. Sango,
    7. M. E. Feeney,
    8. M. M. Addo,
    9. M. Lichterfeld,
    10. M. P. Lahaie,
    11. et al
    . 2006. Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes. Nat. Immunol. 7: 173–178.
    OpenUrlCrossRefPubMed
    1. Ruckwardt T. J.,
    2. C. Luongo,
    3. A. M. Malloy,
    4. J. Liu,
    5. M. Chen,
    6. P. L. Collins,
    7. B. S. Graham
    . 2010. Responses against a subdominant CD8+ T cell epitope protect against immunopathology caused by a dominant epitope. J. Immunol. 185: 4673–4680.
    OpenUrlAbstract/FREE Full Text
  47. ↵
    1. Billam P.,
    2. K. L. Bonaparte,
    3. J. Liu,
    4. T. J. Ruckwardt,
    5. M. Chen,
    6. A. B. Ryder,
    7. R. Wang,
    8. P. Dash,
    9. P. G. Thomas,
    10. B. S. Graham
    . 2011. T Cell receptor clonotype influences epitope hierarchy in the CD8+ T cell response to respiratory syncytial virus infection. J. Biol. Chem. 286: 4829–4841.
    OpenUrlAbstract/FREE Full Text
  48. ↵
    1. Venturi V.,
    2. D. A. Price,
    3. D. C. Douek,
    4. M. P. Davenport
    . 2008. The molecular basis for public T-cell responses? Nat. Rev. Immunol. 8: 231–238.
    OpenUrlCrossRefPubMed
    1. Turner S. J.,
    2. P. C. Doherty,
    3. J. McCluskey,
    4. J. Rossjohn
    . 2006. Structural determinants of T-cell receptor bias in immunity. Nat. Rev. Immunol. 6: 883–894.
    OpenUrlCrossRefPubMed
  50. ↵
    1. Li H.,
    2. C. Ye,
    3. G. Ji,
    4. J. Han
    . 2012. Determinants of public T cell responses. Cell Res. 22: 33–42.
    OpenUrlCrossRefPubMed
  51. ↵
    1. Richeldi L.,
    2. R. Sorrentino,
    3. C. Saltini
    . 1993. HLA-DPB1 glutamate 69: a genetic marker of beryllium disease. Science 262: 242–244.
    OpenUrlAbstract/FREE Full Text
  52. ↵
    1. Maier L. A.,
    2. D. S. McGrath,
    3. H. Sato,
    4. P. Lympany,
    5. K. Welsh,
    6. R. Du Bois,
    7. L. Silveira,
    8. A. P. Fontenot,
    9. R. T. Sawyer,
    10. E. Wilcox,
    11. L. S. Newman
    . 2003. Influence of MHC class II in susceptibility to beryllium sensitization and chronic beryllium disease. J. Immunol. 171: 6910–6918.
    OpenUrlAbstract/FREE Full Text
  53. ↵
    1. Rosenman K. D.,
    2. M. Rossman,
    3. V. Hertzberg,
    4. M. J. Reilly,
    5. C. Rice,
    6. E. Kanterakis,
    7. D. Monos
    . 2011. HLA class II DPB1 and DRB1 polymorphisms associated with genetic susceptibility to beryllium toxicity. Occup. Environ. Med. 68: 487–493.
    OpenUrlAbstract/FREE Full Text
  54. ↵
    1. Amicosante M.,
    2. F. Berretta,
    3. M. Rossman,
    4. R. H. Butler,
    5. P. Rogliani,
    6. E. van den Berg-Loonen,
    7. C. Saltini
    . 2005. Identification of HLA-DRPheβ47 as the susceptibility marker of hypersensitivity to beryllium in individuals lacking the berylliosis-associated supratypic marker HLA-DPGluβ69. Respir. Res. 6: 94.
    OpenUrlCrossRefPubMed
  55. ↵
    1. Rossman M. D.,
    2. J. Stubbs,
    3. C. W. Lee,
    4. E. Argyris,
    5. E. Magira,
    6. D. Monos
    . 2002. Human leukocyte antigen class II amino acid epitopes: susceptibility and progression markers for beryllium hypersensitivity. Am. J. Respir. Crit. Care Med. 165: 788–794.
    OpenUrlCrossRefPubMed
    1. Silveira L. J.,
    2. E. C. McCanlies,
    3. T. E. Fingerlin,
    4. M. V. Van Dyke,
    5. M. M. Mroz,
    6. M. Strand,
    7. A. P. Fontenot,
    8. N. Bowerman,
    9. D. M. Dabelea,
    10. C. R. Schuler,
    11. et al
    . 2012. Chronic beryllium disease, HLA-DPB1, and the DP peptide binding groove. J. Immunol. 189: 4014–4023.
    OpenUrlAbstract/FREE Full Text
  57. ↵
    1. Wang Z.,
    2. P. S. White,
    3. M. Petrovic,
    4. O. L. Tatum,
    5. L. S. Newman,
    6. L. A. Maier,
    7. B. L. Marrone
    . 1999. Differential susceptibilities to chronic beryllium disease contributed by different Glu69 HLA-DPB1 and -DPA1 alleles. J. Immunol. 163: 1647–1653.
    OpenUrlAbstract/FREE Full Text
  58. ↵
    1. Van Dyke M. V.,
    2. J. W. Martyny,
    3. M. M. Mroz,
    4. L. J. Silveira,
    5. M. Strand,
    6. T. E. Fingerlin,
    7. H. Sato,
    8. L. S. Newman,
    9. L. A. Maier
    . 2011. Risk of chronic beryllium disease by HLA-DPB1 E69 genotype and beryllium exposure in nuclear workers. Am. J. Respir. Crit. Care Med. 183: 1680–1688.
    OpenUrlCrossRefPubMed
  59. ↵
    1. Richeldi L.,
    2. K. Kreiss,
    3. M. M. Mroz,
    4. B. Zhen,
    5. P. Tartoni,
    6. C. Saltini
    . 1997. Interaction of genetic and exposure factors in the prevalence of berylliosis. Am. J. Ind. Med. 32: 337–340.
    OpenUrlCrossRefPubMed
  60. ↵
    1. Fontenot A. P.,
    2. M. Torres,
    3. W. H. Marshall,
    4. L. S. Newman,
    5. B. L. Kotzin
    . 2000. Beryllium presentation to CD4+ T cells underlies disease-susceptibility HLA-DP alleles in chronic beryllium disease. Proc. Natl. Acad. Sci. USA 97: 12717–12722.
    OpenUrlAbstract/FREE Full Text
  61. ↵
    1. Lombardi G.,
    2. C. Germain,
    3. J. Uren,
    4. M. T. Fiorillo,
    5. R. M. du Bois,
    6. W. Jones-Williams,
    7. C. Saltini,
    8. R. Sorrentino,
    9. R. Lechler
    . 2001. HLA-DP allele-specific T cell responses to beryllium account for DP-associated susceptibility to chronic beryllium disease. J. Immunol. 166: 3549–3555.
    OpenUrlAbstract/FREE Full Text
  62. ↵
    1. Amicosante M.,
    2. F. Berretta,
    3. R. Dweik,
    4. C. Saltini
    . 2009. Role of high-affinity HLA-DP specific CLIP-derived peptides in beryllium binding to the HLA-DPGlu69 berylliosis-associated molecules and presentation to beryllium-sensitized T cells. Immunology 128(1, Suppl.)e462–e470.
    OpenUrlCrossRefPubMed
  63. ↵
    1. Dai S.,
    2. G. A. Murphy,
    3. F. Crawford,
    4. D. G. Mack,
    5. M. T. Falta,
    6. P. Marrack,
    7. J. W. Kappler,
    8. A. P. Fontenot
    . 2010. Crystal structure of HLA-DP2 and implications for chronic beryllium disease. Proc. Natl. Acad. Sci. USA 107: 7425–7430.
    OpenUrlAbstract/FREE Full Text
  64. ↵
    1. Falta M. T.,
    2. C. Pinilla,
    3. D. G. Mack,
    4. A. N. Tinega,
    5. F. Crawford,
    6. M. Giulianotti,
    7. R. Santos,
    8. G. M. Clayton,
    9. Y. Wang,
    10. X. Zhang,
    11. et al
    . 2013. Identification of beryllium-dependent peptides recognized by CD4+ T cells in chronic beryllium disease. J. Exp. Med. 210: 1403–1418.
    OpenUrlAbstract/FREE Full Text
  65. ↵
    1. Díaz G.,
    2. B. Cañas,
    3. J. Vazquez,
    4. C. Nombela,
    5. J. Arroyo
    . 2005. Characterization of natural peptide ligands from HLA-DP2: new insights into HLA-DP peptide-binding motifs. Immunogenetics 56: 754–759.
    OpenUrlCrossRefPubMed
  66. ↵
    1. Roney K.,
    2. E. Holl,
    3. J. Ting
    . 2013. Immune plexins and semaphorins: old proteins, new immune functions. Protein Cell 4: 17–26.
    OpenUrlCrossRefPubMed
  67. ↵
    1. Clayton G. M.,
    2. Y. Wang,
    3. F. Crawford,
    4. A. Novikov,
    5. B. T. Wimberly,
    6. J. S. Kieft,
    7. M. T. Falta,
    8. N. A. Bowerman,
    9. P. Marrack,
    10. A. P. Fontenot,
    11. et al
    . 2014. Structural basis of chronic beryllium disease: linking allergic hypersensitivity and autoimmunity. Cell 158: 132–142.
    OpenUrlCrossRefPubMed
  68. ↵
    1. Gilchrist F. C.,
    2. M. Bunce,
    3. P. A. Lympany,
    4. K. I. Welsh,
    5. R. M. du Bois
    . 1998. Comprehensive HLA-DP typing using polymerase chain reaction with sequence-specific primers and 95 sequence-specific primer mixes. Tissue Antigens 51: 51–61.
    OpenUrlCrossRefPubMed
  69. ↵
    1. Cho H.,
    2. W. Wang,
    3. R. Kim,
    4. H. Yokota,
    5. S. Damo,
    6. S. H. Kim,
    7. D. Wemmer,
    8. S. Kustu,
    9. D. Yan
    . 2001. BeF(3)(-) acts as a phosphate analog in proteins phosphorylated on aspartate: structure of a BeF(3)(-) complex with phosphoserine phosphatase. Proc. Natl. Acad. Sci. USA 98: 8525–8530.
    OpenUrlAbstract/FREE Full Text
  70. ↵
    1. Martin S.,
    2. H. U. Weltzien
    . 1994. T cell recognition of haptens, a molecular view. Int. Arch. Allergy Immunol. 104: 10–16.
    OpenUrlCrossRefPubMed
  71. ↵
    1. Yin L.,
    2. F. Crawford,
    3. P. Marrack,
    4. J. W. Kappler,
    5. S. Dai
    . 2012. T-cell receptor (TCR) interaction with peptides that mimic nickel offers insight into nickel contact allergy. Proc. Natl. Acad. Sci. USA 109: 18517–18522.
    OpenUrlAbstract/FREE Full Text
  72. ↵
    1. Finch G. L.,
    2. M. D. Hoover,
    3. F. F. Hahn,
    4. K. J. Nikula,
    5. S. A. Belinsky,
    6. P. J. Haley,
    7. W. C. Griffith
    . 1996. Animal models of beryllium-induced lung disease. Environ. Health Perspect. 104(Suppl. 5): 973–979.
    OpenUrlCrossRefPubMed
  73. ↵
    1. Tarantino-Hutchison L. M.,
    2. C. Sorrentino,
    3. A. Nadas,
    4. Y. Zhu,
    5. E. M. Rubin,
    6. S. S. Tinkle,
    7. A. Weston,
    8. T. Gordon
    . 2009. Genetic determinants of sensitivity to beryllium in mice. J. Immunotoxicol. 6: 130–135.
    OpenUrlCrossRefPubMed
  74. ↵
    1. Mack D. G.,
    2. M. T. Falta,
    3. A. S. McKee,
    4. A. K. Martin,
    5. P. L. Simonian,
    6. F. Crawford,
    7. T. Gordon,
    8. R. R. Mercer,
    9. M. D. Hoover,
    10. P. Marrack,
    11. et al
    . 2014. Regulatory T cells modulate granulomatous inflammation in an HLA-DP2 transgenic murine model of beryllium-induced disease. Proc. Natl. Acad. Sci. USA 111: 8553–8558.
    OpenUrlAbstract/FREE Full Text
  75. ↵
    1. Büdinger L.,
    2. M. Hertl
    . 2000. Immunologic mechanisms in hypersensitivity reactions to metal ions: an overview. Allergy 55: 108–115.
    OpenUrlCrossRefPubMed
  76. ↵
    1. Moulon C.,
    2. J. Vollmer,
    3. H. U. Weltzien
    . 1995. Characterization of processing requirements and metal cross-reactivities in T cell clones from patients with allergic contact dermatitis to nickel. Eur. J. Immunol. 25: 3308–3315.
    OpenUrlCrossRefPubMed
  77. ↵
    1. Emtestam L.,
    2. H. Zetterquist,
    3. O. Olerup
    . 1993. HLA-DR, -DQ and -DP alleles in nickel, chromium, and/or cobalt-sensitive individuals: genomic analysis based on restriction fragment length polymorphisms. J. Invest. Dermatol. 100: 271–274.
    OpenUrlCrossRefPubMed
  78. ↵
    1. Sinigaglia F.,
    2. D. Scheidegger,
    3. G. Garotta,
    4. R. Scheper,
    5. M. Pletscher,
    6. A. Lanzavecchia
    . 1985. Isolation and characterization of Ni-specific T cell clones from patients with Ni-contact dermatitis. J. Immunol. 135: 3929–3932.
    OpenUrlAbstract
  79. ↵
    1. Romagnoli P.,
    2. A. M. Labhardt,
    3. F. Sinigaglia
    . 1991. Selective interaction of Ni with an MHC-bound peptide. EMBO J. 10: 1303–1306.
    OpenUrlPubMed
  80. ↵
    1. Lu L.,
    2. J. Vollmer,
    3. C. Moulon,
    4. H. U. Weltzien,
    5. P. Marrack,
    6. J. Kappler
    . 2003. Components of the ligand for a Ni++ reactive human T cell clone. J. Exp. Med. 197: 567–574.
    OpenUrlAbstract/FREE Full Text
  81. ↵
    1. Illing P. T.,
    2. J. P. Vivian,
    3. A. W. Purcell,
    4. J. Rossjohn,
    5. J. McCluskey
    . 2013. Human leukocyte antigen-associated drug hypersensitivity. Curr. Opin. Immunol. 25: 81–89.
    OpenUrlCrossRefPubMed
  82. ↵
    1. Illing P. T.,
    2. J. P. Vivian,
    3. N. L. Dudek,
    4. L. Kostenko,
    5. Z. Chen,
    6. M. Bharadwaj,
    7. J. J. Miles,
    8. L. Kjer-Nielsen,
    9. S. Gras,
    10. N. A. Williamson,
    11. et al
    . 2012. Immune self-reactivity triggered by drug-modified HLA-peptide repertoire. Nature 486: 554–558.
    OpenUrlPubMed
  83. ↵
    1. Ostrov D. A.,
    2. B. J. Grant,
    3. Y. A. Pompeu,
    4. J. Sidney,
    5. M. Harndahl,
    6. S. Southwood,
    7. C. Oseroff,
    8. S. Lu,
    9. J. Jakoncic,
    10. C. A. de Oliveira,
    11. et al
    . 2012. Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire. Proc. Natl. Acad. Sci. USA 109: 9959–9964.
    OpenUrlAbstract/FREE Full Text
  84. ↵
    1. Fontenot A. P.,
    2. T. S. Keizer,
    3. M. McCleskey,
    4. D. G. Mack,
    5. R. Meza-Romero,
    6. J. Huan,
    7. D. M. Edwards,
    8. Y. K. Chou,
    9. A. A. Vandenbark,
    10. B. Scott,
    11. G. G. Burrows
    . 2006. Recombinant HLA-DP2 binds beryllium and tolerizes beryllium-specific pathogenic CD4+ T cells. J. Immunol. 177: 3874–3883.
    OpenUrlAbstract/FREE Full Text
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section